Psyence Biomedical 1/23/2025 Earnings Report

Psyence Biomedical EPS Results

• Actual EPS: $4.06
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Psyence Biomedical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Psyence Biomedical Announcement Details

• Date: 1/23/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Psyence Biomedical (NASDAQ:PBM), Inc. is a clinical-stage biotechnology company focused on developing innovative drug delivery solutions for neuropsychiatric and pain indications. Founded in 2020 and headquartered in Houston, Texas, the company’s proprietary technology platform centers on a biodegradable, microneedle patch designed for transdermal administration of therapeutic compounds. By harnessing this novel delivery approach, Psyence Biomedical aims to improve patient compliance, enhance bioavailability and offer controlled dosing of established and emerging investigational molecules.

The company’s lead product candidate leverages its microneedle system to administer a low-dose psychedelic compound for the potential treatment of depression, anxiety and other mood disorders. This patch technology is designed to allow for rapid onset, sustained release and minimal invasiveness compared with traditional oral or intravenous routes. In addition to its flagship program, Psyence Biomedical is exploring applications of its platform for acute and chronic pain relief using non-opioid analgesics. Preclinical studies have demonstrated promising pharmacokinetic profiles, and the company is advancing toward first-in-human trials in collaboration with academic research centers.

Psyence Biomedical serves markets in North America and Europe through strategic partnerships and research alliances aimed at accelerating clinical development and regulatory approval. The company benefits from a leadership team with deep experience in pharmaceutical development, medical device engineering and commercial operations. Chief Executive Officer Dr. Michelle Alvarez, who has over two decades of industry experience, is supported by Chief Scientific Officer Dr. Rahul Patel and a board of directors with expertise spanning biotechnology, venture capital and healthcare policy.